Skip to content

Safety and efficacy of endoscopic resection of upper gastrointestinal extraluminal tumors and predominantly extraluminal tumors

Safety and efficacy of endoscopic resection of upper gastrointestinal extraluminal tumors and predominantly extraluminal tumors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072476
Enrollment
Unknown
Registered
2023-06-14
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal extraluminal tumors

Interventions

Tset group:endoscopic resection

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Age 18-80 years old; ? CT and EUS examinations confirm that the tumor is mainly located outside the lumen of the gastrointestinal tract (>50%) or originates from tissues around the gastrointestinal tract, such as the mediastinum, omentum, and mesentery; ? The maximum cross-sectional diameter of the lesion is =5.0cm; ? Chest and abdomen CT showed no definite metastases; ? Neoadjuvant therapy and targeted therapy were not performed before operation; ? Preoperative physical condition score (ECOG, Eastern Cooperative Oncology Group) 0 or 1; ? Preoperative American Society of Anesthesiologists ASA (American Society of Anesthesiologists) grade I-III; ? The function of important organs is sound; ? Sign the informed consent form.

Exclusion criteria

Exclusion criteria: ? Pregnant and lactating women; ? History of malignant tumors at the same time or at different times (within 5 years); ? Preoperative body temperature = 38 ? or patients with infectious diseases who need systemic treatment; ? Patients with severe mental illness; ? Severe cardiopulmonary disease, severe renal insufficiency not suitable for general anesthesia; ? People with coagulation dysfunction; ? Unstable angina or a history of myocardial infarction within 6 months; ? History of cerebral infarction or cerebral hemorrhage within 6 months; ? Continuous use of systemic hormone therapy within 1 month; ? Combined with other diseases that can be intervened by surgery at the same time, such as gallbladder stones, etc.; ? Patients who have participated or are currently participating in other clinical trials within 6 months.

Design outcomes

Primary

MeasureTime frame
adverse events ;

Secondary

MeasureTime frame
en bloc resection rate;operative time;Hospitalization days;Postoperative rehabilitation status;

Countries

China

Contacts

Public ContactZhou pinghong

Zhongshan Hospital, Fudan University

zhou.pinghong@zs-hospital.sh.cn+86 136 8197 1063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026